NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer established a favorable safety profile and...

Related Keywords

Texas ,United States ,Massachusetts ,China ,Paris ,France General ,France ,Cambridge ,Cambridgeshire ,United Kingdom ,New York ,Pierre Louis Germain ,Christophe Le Tourneau ,Brandon Owens ,Louis Kayitalire ,Ligia Vela Reid ,Exchange Commission ,Given The Company ,Linkedin ,Drug Administration ,Nasdaq ,Investor Relations Department ,University Of Texas Md Anderson Cancer Center ,French Financial Markets Authority Autorit ,Euronext ,Twitter ,European Society For Medical Oncology ,Communications Department ,Strategic Collaborator Presented Phase ,Overall Survival ,All Patients Treated ,Objective Response ,Progression Free Survival ,European Society ,Medical Oncology ,Endoscopic Ultrasound ,Locally Advanced ,Borderline Resectable Pancreatic Cancer ,Cancer Center ,Antitumor Activity ,Injected Lesions ,Estimate Overall Survival ,Exploratory Analyses ,Cisplatin Ineligible Locally Advanced ,Local Progression Free Survival ,Professor Christophe Le Tourneau ,United States Food ,Fast Track ,Greater China ,Asian Markets ,Janssen Pharmaceutica ,Euronext Paris ,Nasdaq Global Select Market ,New York City ,Private Securities Litigation Reform Act ,Annual Report ,French Financial Markets Authority ,Des March ,Markets ,